# OnCo record nct06881784 (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/nct06881784/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "nct06881784", "NCT06881784" ;
  schema:name "Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301)"@en ;
  schema:alternateName "RASolve 301"@en ;
  schema:description "A phase 3 trial of Daraxonrasib, Docetaxel in non-small-cell lung cancer and small-cell lung cancer, run by Revolution Medicines, Inc., now recruiting."@en ;
  schema:url <https://onco.cc/trials/nct06881784/> ;
  schema:dateModified "2026-09-16"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT06881784> ;
  onco:status "recruiting" ;
  onco:tag "ctgov-ingest" ;
  onco:phase "3" ;
  schema:startDate "2025-05-06" ;
  onco:cancers <https://onco.cc/cancers/nsclc/>, <https://onco.cc/cancers/sclc/> ;
  onco:technologies <https://onco.cc/technologies/cytotoxic-chemotherapy/>, <https://onco.cc/technologies/kras-inhibitors/> ;
  onco:drugs <https://onco.cc/drugs/daraxonrasib/>, <https://onco.cc/drugs/docetaxel/> ;
  onco:companies <https://onco.cc/companies/revolution-medicines/> .